Back to top

Analyst Blog

Zacks Equity Research

Major Setback for Aeterna Zentaris

OSIR CYTK

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Aeterna Zentaris Inc. recently received a setback when an independent Data Safety Monitoring Board (DSMB) recommended the discontinuation of a phase III study on its oncology candidate perifosine. The study was evaluating the efficacy and safety of perifosine in combination with Takeda Pharmaceutical Company Limited’s Velcade (bortezomib) and dexamethasone versus placebo in relapsed or relapsed/refractory multiple myeloma patients.

The independent DSMB recommended the discontinuation of the phase III study as there was very little chance of the study meeting its primary endpoint and achieving significant progression free survival. However, the DSMB did not raise any safety concerns related to the use of perifosine

Perifosine enjoys an orphan drug designation in both the US and the EU for the treatment of multiple myeloma. The US Food and Drug Administration has also granted the candidate a fast track status.

Perifosine is also being evaluated for multiple oncology indications including renal cell carcinoma (phase II), non-small cell lung cancer (phase II), breast cancer (phase II) and neuroblastoma (phase I). 

We note that the discontinuation of the phase III study evaluating perifosine for relapsed or relapsed/refractory multiple myeloma is a huge disappointment for Aeterna Zentaris. The study was being conducted under FDA’s Special Protocol Assessment program. Aeterna Zentaris had planned regulatory submission based on the potential data from the study.

Aeterna Zentaris currently carries a Zacks Rank #3 (Hold). Stocks that currently look attractive in the pharma space include companies like Cytokinetics, Inc. (CYTK - Snapshot Report) and Osiris Therapeutics, Inc. (OSIR - Analyst Report) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%